Navigation Links
Halozyme Reports First Quarter 2012 Financial Results

SAN DIEGO, May 7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2012.


"We achieved a significant milestone in the first quarter with the European regulatory filing of the subcutaneous Herceptin program by our partner Roche," said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. "Despite the HyQ regulatory delay from our Baxter collaboration, our pipeline has continued to make tangible progress on all fronts, as well as across diverse therapeutic areas and geographies."

First Quarter Highlights Highlights of Halozyme's first quarter activities and recent events include:

  • Notification from the European Patent Office (EPO) that a hearing scheduled in opposition of the European patent for Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) was cancelled and the EPO acknowledged the patentability of the claims. The Company anticipates the EPO to issue a final written decision to this effect.
  • Announced with our collaborator, Baxter, that the U.S. Food and Drug Administration (FDA) requested additional information to complete its review of the HyQ Biologics License Application (BLA).The Companies will work together to develop studies to provide additional data to address the concerns raised by the agency.
  • In addition to filing a Line Extension Application for subcutaneous (SC) Herceptin® (trastuzumab) with the European Medicines Agency (EMA), Roche presented Phase 3 registration data from the HannaH trial at the Early Breast Cancer Conference in Vienna. The study met its co-primary endpoints of pharmacokinetics and efficacy. Herceptin SC, using rHuPH20, may provide greater convenience to patients versus the traditional IV method due to its less invasive administration route and quicker administration time (5 minutes versus 30 – 90 minutes).  
  • Roche reiterated their intent to file the Line Extension Application of subcutaneous MabThera® (rituxumab with rHuPH20) to the EMA this year for the treatment of Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Follicular Lymphoma.
  • Announced positive data with ViroPharma regarding a Phase 2 SC trial of Cinryze® (C1 esterase inhibitor [human]) in combination with rHuPH20, in patients with hereditary angioedema. Presented at the American Academy of Allergy Asthma & Immunology, the study demonstrated that SC co-administration of Cinryze with rHuPH20 was well tolerated and resulted in sustained physiologically relevant C1 INH functional concentrations.
  • Updated the Hylenex® recombinant (hyaluronidase human injection) label to include instructions for pre-administration of the enzyme in advance of other injected or subcutaneously infused drugs, and information from non-clinical studies that provide further data on the safety profile of Hylenex.
  • First Quarter 2012 Financial ResultsThe net loss for the first quarter of 2012 was $15.1 million, or $0.14 per share, compared with a net loss for the first quarter of 2011 of $9.6 million, or $0.10 per share.

  • Revenues for the first quarter of 2012 were $7.4 million, compared to $7.5 million for the first quarter of 2011. Revenues in the first quarter of 2012 primarily consisted of a milestone payment from Roche of $4 million and research and development reimbursements from partners.
  • Research and development expenses for the first quarter of 2012 were $15.9 million, compared with $13.8 million for the first quarter of 2011, primarily due to an increase in manufacturing activities and compensation costs, partially offset by a decrease in clinical trial activities. 
  • Selling, general and administrative (SG&A) expenses for the first quarter of 2012 were $6.6 million, compared to $3.4 million for the first quarter of 2011. The increase for SG&A was due to higher compensation costs and higher marketing and market research expenses during the quarter. 
  • Cash and cash equivalents were $116.6 million as of March 31, 2012, compared with $73.8 million as of March 31, 2011. Excluding the net proceeds of $81.5 million from the financing in February 2012, net cash used in the first quarter of 2012 was approximately $17.7 million.
  • Due to the HyQ regulatory delay, we anticipate 2012 cash burn to be $55-$60 million, instead of $50-$55 million as previously forecasted.

    Conference CallHalozyme will webcast its Quarterly Update Conference Call today at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, Ph.D., Halozyme's President and Chief Executive Officer, will lead the call. During the call, the Company plans to provide further details underlying its first quarter 2012 financial results. To access the webcast, please log on to approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

    Upcoming Corporate PresentationsHalozyme is scheduled to present at the upcoming investor conference.

  • Bank of America Merrill Lynch 2012 Healthcare Conference in Las Vegas on May 16, 2012 at 1:00 p.m. ET/10:00 a.m. PT. Gregory I. Frost, Ph.D., President and Chief Executive Officer of Halozyme Therapeutics, will provide a corporate overview.
  • The presentation will be webcast through the "Investors" section of Halozyme's corporate website at, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

    About Halozyme Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at

    Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the EPO's anticipated issuance of a final written decision regarding our European patent for rHuPH20, Roche's anticipated filing of the Line Extension Application of subcutaneous MabThera® (rituxumab with rHuPH20) to the European Medicines Agency this year, our anticipated cash burn for 2012  and potential benefits and attributes of our product candidates. These statements involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures, clinical trial results, delays in development and regulatory review, regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

    Media/Investor Contact:
    Anne Erickson
    Executive Director
    Halozyme Therapeutics
    858-704-8264 Halozyme Therapeutics, Inc.Unaudited Condensed Consolidated Statements of OperationsThree Months Ended March 31,20122011REVENUES:Product sales, net

    87,411$165,449Revenues under collaborative agreements

    7,252,7687,378,445Total revenues

    7,440,1797,543,894OPERATING EXPENSES:Cost of product sales

    70,76111,717Research and development

    15,891,10913,785,797Selling, general and administrative

    6,618,7073,405,966Total operating expenses

    22,580,57717,203,480OPERATING LOSS

    (15,140,398)(9,659,586)Interest and other income, net

    21,21723,869NET LOSS

    $  (15,119,181)$ (9,635,717)Basic and diluted net loss per share

    (0.10)Shares used in computing basic and diluted net loss per share

    107,589,514100,927,402 Halozyme Therapeutics, Inc.Unaudited Condensed Consolidated Balance SheetsMarch 31,December 31,20122011ASSETSCurrent assets:Cash and cash equivalents

    52,825,527Accounts receivable, net


    1,496,783567,263Prepaid expenses and other assets

    8,910,0598,332,242Total current assets

    132,565,97663,987,497Property and equipment, net

    2,152,9341,771,048Total Assets

    5,758,545LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    7,556,859Accrued expenses

    7,184,7945,615,574Deferred revenue, current portion

    6,484,8004,129,407Total current liabilities

    16,680,77517,301,840Deferred revenue, net of current portion

    36,130,76736,754,583Deferred rent, net of current portion

    846,957802,006Stockholders' equity:Common stock

    112,411103,990Additional paid-in capital

    341,088,827255,817,772Accumulated deficit

    (260,140,827)(245,021,646)Total stockholders' equity

    81,060,41110,900,116Total Liabilities and Stockholders' Equity



    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    2. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
    3. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
    4. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
    5. Halozyme Announces Proposed Public Offering of Common Stock
    6. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
    7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
    8. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
    9. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
    10. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
    11. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
    Post Your Comments:
    (Date:3/27/2017)... , March 27, 2017 ... better understand Bayer and its partnering interests and activities since ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ... data. The report will be delivered in PDF ...
    (Date:3/27/2017)... -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company") ... common stock in an underwritten public offering under an ... and Exchange Commission (the "SEC"). The offering is subject ... no assurance as to whether or when the offering ... or terms of the offering. Cryoport also expects to ...
    (Date:3/27/2017)... 2017  A new survey from the ... Competitive Bidding Program (CBP) significantly reduced beneficiary choice and ... of choice forces beneficiaries to switch to unfamiliar or ... AADE,s survey is the latest in ... pointing out the inherent problems with the CBP. Last ...
    Breaking Medicine Technology:
    (Date:3/28/2017)... ... ... Silicon Valley Hair Institute, the San Francisco Bay Area leader in women's ... loss. Although hair transplant procedures can be seen as more of a man’s issue, ... two reasons a woman may see her hair thinning. , “We are used to ...
    (Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Bacteria and fungi are probably not the ... are bad. In fact, including the right microorganisms in your diet can actually improve health ... foods. , This is the topic of a new peer-reviewed paper led ...
    (Date:3/27/2017)... ... , ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope and Bilal ... role this treatment plays in protecting oral health, along with the benefits of receiving ... need a root canal in White Plains, NY or their second location in Mt. ...
    (Date:3/27/2017)... Arizona (PRWEB) , ... March 27, 2017 , ... Buzzies ... the top 10 for Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo will ... York on April 8. , Project Entrepreneur’s second annual venture competition ignites bold ...
    (Date:3/27/2017)... , ... March 27, 2017 , ... ... quickly sideline athletes. A type of groin injury, it occurs when the muscles ... serious, intense pain in and around the lower torso, as well as accompanying ...
    Breaking Medicine News(10 mins):